Cargando…

Recent Developments in the Therapeutic Landscape of Advanced or Metastatic Hormone Receptor–Positive Breast Cancer

Hormone receptor–positive (HR+) disease is the most frequently diagnosed subtype of breast cancer. Among tumor subtypes, natural course of HR+ breast cancer is indolent with favorable prognosis compared to other subtypes such as human epidermal growth factor protein 2–positive disease and triple-neg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Eunice Yoojin, Lee, Dae-Won, Lee, Kyung-Hun, Im, Seock-Ah
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582540/ https://www.ncbi.nlm.nih.gov/pubmed/37817306 http://dx.doi.org/10.4143/crt.2023.846

Ejemplares similares

Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea
por: Beom, Seung Hoon, et al.
Publicado: (2017)

Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor?Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors
por: Suh, Koung Jin, et al.
Publicado: (2017)

Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL)
por: Lee, Jiyun, et al.
Publicado: (2021)

Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lee, Soohyeon, et al.
Publicado: (2022)

Therapeutic implication of HER2 in advanced biliary tract cancer
por: Nam, Ah-Rong, et al.
Publicado: (2016)

A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma
por: Lee, Dae-Won, et al.
Publicado: (2018)

Effect of Timing of Gonadotropin-Releasing Hormone Agonist Administration for Ovarian Protection in Patients with Breast Cancer
por: Shin, Jae Jun, et al.
Publicado: (2020)

Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
por: Kim, Jee Hyun, et al.
Publicado: (2021)

Hormone Receptor–Positive, HER2-Negative Breast Cancer: Recent Advances and Best Practices
por: Schwartzberg, Lee, et al.
Publicado: (2020)

Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy
por: Kim, Seongyeong, et al.
Publicado: (2021)

Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
por: Lee, Soohyeon, et al.
Publicado: (2020)

A Real-World Efficacy of Nab-Paclitaxel Monotherapy in Metastatic Breast Cancer
por: Kim, Jung Sun, et al.
Publicado: (2022)

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
por: Schmid, Peter, et al.
Publicado: (2021)

The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy
por: Choi, Younak, et al.
Publicado: (2016)

More Accurate Prediction of Metastatic Pancreatic Cancer Patients’ Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity
por: Choi, Younak, et al.
Publicado: (2016)

Talazoparib versus Chemotherapy in Patients with HER2-Negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

Leptin as a Potential Target for Estrogen Receptor-Positive Breast Cancer
por: Yom, Cha Kyong, et al.
Publicado: (2013)

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
por: Min, Ahrum, et al.
Publicado: (2020)

Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index
por: Choi, Younak, et al.
Publicado: (2015)

Biological characteristics and treatment outcomes of metastatic or recurrent neuroendocrine tumors: tumor grade and metastatic site are important for treatment strategy
por: Kim, Su-Jung, et al.
Publicado: (2010)

Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer
por: Lee, Eun-Shin, et al.
Publicado: (2016)

Metastatic Hormone-sensitive Prostate Cancer: Current Perspective on the Evolving Therapeutic Landscape
por: Hall, Mary E, et al.
Publicado: (2020)

CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy
por: Lee, Dae-Won, et al.
Publicado: (2017)

Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer
por: Cha, Yongjun, et al.
Publicado: (2016)

Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy
por: Cho, Kyoung-Min, et al.
Publicado: (2017)

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
por: Ballinger, Tarah J., et al.
Publicado: (2018)

TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials
por: Lee, Dae-Won, et al.
Publicado: (2016)

Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer
por: Kim, Jisun, et al.
Publicado: (2012)

A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
por: Lee, Dae-Won, et al.
Publicado: (2023)

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer
por: Park, Yeon Hee, et al.
Publicado: (2023)

Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer
por: Cho, Kyoung-Min, et al.
Publicado: (2016)

Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor–Positive Breast Cancer
por: Sarma, Maithreyi, et al.
Publicado: (2020)

Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer: A Multicenter Retrospective Study
por: Park, Jin Hyun, et al.
Publicado: (2017)

Recent advances in the treatment of hormone receptor-positive/human epidermal growth factor 2-positive advanced breast cancer
por: Lv, Huimin, et al.
Publicado: (2021)

Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer
por: Lee, Kyung-Min, et al.
Publicado: (2020)

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies
por: Ettl, Johannes, et al.
Publicado: (2020)

Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
por: Bansal, Pranshu, et al.
Publicado: (2016)

Prospective longitudinal analysis of antibody response after standard and booster doses of SARS-COV2 vaccination in patients with early breast cancer
por: Kim, Jinyong, et al.
Publicado: (2022)

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients
por: Iwata, Hiroji, et al.
Publicado: (2017)

Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment
por: Kim, Jinyong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r5qbgf3iadap7mhfn0idv1m36i